There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
Examples over the past month include:
There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
Examples over the past month include: